Integral Health Asset Management LLC Has $19.43 Million Stock Position in uniQure (NASDAQ:QURE)

Integral Health Asset Management LLC increased its stake in shares of uniQure (NASDAQ:QURE - Free Report) by 175.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,100,000 shares of the biotechnology company's stock after acquiring an additional 700,000 shares during the quarter. uniQure comprises approximately 1.7% of Integral Health Asset Management LLC's holdings, making the stock its 20th largest holding. Integral Health Asset Management LLC owned 2.26% of uniQure worth $19,426,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Avoro Capital Advisors LLC bought a new stake in uniQure in the 4th quarter valued at $38,410,000. Franklin Resources Inc. increased its holdings in uniQure by 33.1% in the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock valued at $35,103,000 after buying an additional 494,726 shares during the period. Boxer Capital Management LLC bought a new stake in uniQure in the 4th quarter valued at $13,245,000. Invesco Ltd. increased its holdings in uniQure by 453.2% in the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock valued at $10,836,000 after buying an additional 502,684 shares during the period. Finally, Schonfeld Strategic Advisors LLC bought a new stake in uniQure in the 4th quarter valued at $9,473,000. Institutional investors own 78.83% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on QURE shares. Chardan Capital reissued a "buy" rating and issued a $38.00 price target on shares of uniQure in a report on Monday, May 12th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. StockNews.com raised shares of uniQure to a "sell" rating in a report on Tuesday, March 11th. Wells Fargo & Company lowered their target price on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $28.00 target price on shares of uniQure in a report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $37.82.

uniQure Price Performance

NASDAQ QURE traded up $0.45 on Friday, hitting $13.70. 1,614,113 shares of the company were exchanged, compared to its average volume of 1,883,424. The firm has a 50 day moving average of $12.31 and a two-hundred day moving average of $12.32. The company has a market cap of $750.43 million, a P/E ratio of -2.76 and a beta of 0.10. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. On average, equities analysts predict that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling at uniQure

In related news, CEO Matthew C. Kapusta sold 6,717 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the sale, the chief executive officer now directly owns 580,795 shares in the company, valued at $6,574,599.40. This trade represents a 1.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Christian Klemt sold 10,438 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $107,407.02. Following the completion of the sale, the chief financial officer now owns 217,730 shares in the company, valued at $2,240,441.70. This represents a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 90,830 shares of company stock worth $961,401. Company insiders own 4.74% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.